

## Invitation to the presentation of BICO's interim report Q4, 2023

BICO's Interim report for Q4 2023 will be published on Tuesday February 20, 2024, at 07:00am CET. Following the release of the report, a telephone conference with the opportunity to ask questions will be held in English at 10:00 am CET on the same day, with President & CEO Maria Forss and CFO Jacob Thordenberg presenting the report.

### Information about the presentation and webcast

The presentation will be available on BICO's website from 09:00am CET.

<https://bico.com/investors/>

If you wish to participate via webcast, please use the link below:

<https://ir.financialhearings.com/bico-q4-2023>

If you wish to participate via teleconference, please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via teleconference.

<https://conference.financialhearings.com/teleconference/?id=5004043>

### For further information, please contact:

Jacob Thordenberg, CFO, BICO Group AB

Phone: +46 735 34 88 84

E-mail: [jt@bico.com](mailto:jt@bico.com)

*The information was submitted for publication, through the agency of the contact person set out above, on February 12, 2024 at 07.00am CET.*

### About BICO

BICO is a leading provider of life science solutions and laboratory automation that enable more efficient development of new treatments with more specificity and less need for animal testing.

The company uses bioconvergence as its operating system, combining advanced technologies with biology to streamline and automate workflows within the pharmaceutical and biopharma industries.

With 32,000+ instruments installed in over 65 countries, BICO products and solutions are found in more than 3,500 laboratories, including the world's top 20 pharmaceutical companies, and have been cited in over 11,000 publications.

Operating through three business areas – Bioprinting, Biosciences and Bioautomation – the BICO Group strives towards the long-term ambition of enabling the reduction of the world's organ shortage and speeding up drug development to create the future of life-saving treatments.

BICO is listed on Mid-Cap, Nasdaq Stockholm under BICO. [www.bico.com](http://www.bico.com)

**PRESS RELEASE**  
12 February 2024 07:00:00 CET



**Attachments**

[Invitation to the presentation of BICO's interim report Q4, 2023](#)